DataSheet_1_Response to SARS-CoV-2 initial series and additional dose vaccine in pediatric patients with predominantly antibody deficiency.docx

Data regarding response to SARS-CoV-2 immunization in pediatric patients with predominantly antibody deficiency (PAD) is limited. We evaluated SARS-CoV-2 immunization response by anti-SARS-CoV-2-spike antibody level in 15 pediatric PAD patients. These data were compared to a published cohort of adult PAD patients (n=62) previously analyzed following SARS-CoV-2 immunization at our single center institution. We evaluated demographics, clinical characteristics, immunophenotype, infection history, and past medication use by chart review. Following a two-dose monovalent initial series SARS-CoV-2 immunization, mean anti-SARS-CoV-2-spike antibody levels were significantly higher in pediatric PAD patients compared to adult PAD patients (2,890.7 vs. 140.1 U/mL; p<0.0001). Pediatric PAD patients with low class-switched memory B-cells, defined as <2% of total CD19+ B-cells, had significantly lower mean anti-SARS-CoV-2-spike antibody levels than those without (p=0.02). Following a third-dose monovalent SARS-CoV-2 immunization, the mean anti-SARS-CoV-2-spike antibody levels in pediatric PAD patients significantly increased (2,890.7 to 18,267.2 U/mL; p<0.0001). These data support Centers for Disease Control guidelines regarding three-part SARS-CoV-2 vaccine series, including in the pediatric PAD patient demographic.

针对以抗体缺陷为主（predominantly antibody deficiency, PAD）的儿科患者的新冠病毒（SARS-CoV-2）疫苗接种应答相关数据较为有限。本研究通过抗新冠病毒刺突抗体水平，对15名儿科PAD患者的新冠疫苗接种应答情况进行了评估。我们将这些数据与本单中心既往已发表的成人PAD患者队列（n=62）进行了对比，该队列曾接受新冠疫苗接种并完成相关分析。本研究通过病历回顾，收集了受试者的人口统计学特征、临床特征、免疫表型、感染史及既往用药情况。在完成2剂单价型新冠疫苗初始免疫程序后，儿科PAD患者的平均抗新冠刺突抗体水平显著高于成人PAD患者（2890.7 vs 140.1 U/mL；p<0.0001）。外周血CD19阳性B细胞占比<2%的类别转换记忆B细胞水平低下的儿科PAD患者，其平均抗新冠刺突抗体水平显著低于该指标正常的患儿（p=0.02）。在接受第3剂单价型新冠疫苗接种后，儿科PAD患者的平均抗新冠刺突抗体水平显著升高（从2890.7升至18267.2 U/mL；p<0.0001）。本研究数据支持美国疾病控制与预防中心（Centers for Disease Control, CDC）针对新冠疫苗3剂次接种程序的指南，其中也涵盖儿科PAD患者人群。